LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (OTCQX: SONX) (“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2023.
Highlights
“We are pleased to have closed the year with a strong installed base and improved operating leverage despite prevailing macroeconomic headwinds. In the fourth quarter we made significant strides in gross margin improvement and cash burn reduction,” said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. “As we start 2024, we are refining our commercial strategy. Following the sale of TDO, our core business is supported by a healthier balance sheet that allows us to acutely focus on GentleWave procedure adoption.”
Fourth Quarter 2023 Financial Results
Total revenue was $11.7 million for the fourth quarter of 2023, an decrease from $12.2 million for the fourth quarter of 2022. GentleWave Console revenue was $2.9 million for the fourth quarter of 2023, a decrease from $3.9 million for the fourth quarter of 2022. Procedure instrument revenue was $5.1 million, an increase from $5.0 million for the fourth quarter of 2022. Software revenue was $2.7 million, an increase from $2.4 million for the fourth quarter of 2022. As of December 31, 2023, ending installed base was 1,134 units, representing growth of approximately 16% compared to December 31, 2022.
Gross margin for the fourth quarter of 2023 was 33%, compared to 27% for the fourth quarter of 2022. During the fourth quarter of 2023, we recorded a $0.2 million charge for impairment of long-lived assets in cost of sales. Excluding this charge, non-GAAP gross margin for the fourth quarter of 2023 would have been 35%.
Total operating expenses for the fourth quarter of 2023 were $13.7 million, compared to $18.1 million for the fourth quarter of 2022.
Loss from operations was $9.9 million for the fourth quarter of 2023, compared to $14.8 million for the fourth quarter of 2022. Non-GAAP loss from operations was $8.0 million for the fourth quarter of 2023 compared to $11.9 million for the fourth quarter of 2022. Non-GAAP loss from operations excludes stock-based compensation expense, depreciation and amortization expense and impairment of long-lived assets.
Net loss was $10.9 million for the fourth quarter of 2023, compared to $10.9 million for the fourth quarter of 2022.
Cash and cash equivalents and short-term investments as of December 31, 2023 totaled $46.8 million.
Full Year 2023 Financial Results
Total revenue was $43.9 million for the full year 2023, an increase from $41.7 million for the full year 2022. GentleWave Console revenue was $9.2 million for 2023, a decrease from $10.8 million for 2022. Procedure instrument revenue was $21.6 million, an increase from $18.9 million for 2022. Software revenue was $9.2 million, an increase from $8.4 million for 2022.
Gross margin for the full year 2023 was 24% , compared to 25% for the full year 2022. During 2023, we recorded a $1.6 million charge for impairment of long-lived assets in cost of sales. Excluding the charges, non-GAAP gross margin for the full year 2023 would have been 28%.
Total operating expenses for 2023 were $68.5 million, compared to $68.7 million for 2022. During 2023, we recorded $2.1 million in impairment charges of long-lived assets in operating expenses.
Loss from operations was $57.7 million for 2023, compared to $58.2 million for 2022. Non-GAAP loss from operations was $45.1 million for 2023, compared to $49.0 million for 2022. Non-GAAP loss from operations excludes stock-based compensation expense, depreciation, amortization expense and impairment of long-lived assets.
Net loss was $60.9 million for 2023 compared to $57.1 million for 2022.
2024 Financial Guidance
The Company expects the full year 2024 total revenue to be in the range of $28.0 million to $30.0 million, which excludes all revenues from the TDO software segment.
Webcast and Conference Call Information
Sonendo will host a conference call to discuss the fourth quarter and full year 2023 financial results after the market close on Monday, March 11, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 426330. Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://investor.sonendo.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Sonendo
Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. In March 2024, Sonendo divested the TDO® Software segment by selling substantially all the assets and liabilities of TDO Software, Inc.
For more information about Sonendo and the GentleWave System, please visit www.sonendo.com. To find a GentleWave doctor in your area, please visit www.gentlewave.com.
Forward Looking Statements
This press release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, express or implied forward-looking statements relating to the Company’s anticipated business and financial performance on an on-going basis and Sonendo’s 2024 financial guidance. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company’s actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the “Risk Factors” set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Use of Non-GAAP Financial Measures
Sonendo’ financial results are prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). This press release and the reconciliation tables included in the financial schedules below include non-GAAP gross profit, non-GAAP gross margin and non-GAAP loss from operations (collectively, the “Non-GAAP measures”). Non-GAAP gross profit and non-GAAP gross margin exclude impairment of long-lived assets. Non-GAAP loss from operations exclude, as applicable, stock-based compensation expense, depreciation and amortization and impairment of long-lived assets. Management believes that Non-GAAP measures are useful in helping identify the company’s core operating performance and enables management to consistently analyze the period-to-period financial performance of the core business operations. Management also believes that Non-GAAP measures, will enable investors to assess the company in the same way that management has historically assessed the company’s operating results against comparable companies with conventional accounting methodologies. The company’s definition for each of the Non-GAAP measures has limitations as an analytical tool and may differ from other companies reporting similarly named measures. Non-GAAP measures should not be considered measures of financial performance under GAAP, and the items excluded from such Non-GAAP measures should not be considered in isolation or as alternatives to financial statement data presented in the financial statements as an indicator of financial performance or liquidity. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.
For a reconciliation of our Non-GAAP measures presented herein to GAAP measures, the most directly comparable GAAP financial measure, please see “Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin” and “Reconciliation of GAAP to Non-GAAP Loss from Operations” in the financial schedules below.
|
SONENDO, INC. |
||||||||
|
CONSOLIDATED BALANCE SHEETS |
||||||||
|
(in thousands, except share data) |
||||||||
|
|
|
December 31, |
|
December 31, |
||||
|
|
|
2023 |
|
|
2022 |
|
||
|
ASSETS |
|
|
|
|
||||
|
Current assets: |
|
|
|
|
||||
|
Cash and cash equivalents |
|
$ |
14,009 |
|
|
$ |
17,665 |
|
|
Short-term investments |
|
|
32,773 |
|
|
|
73,784 |
|
|
Accounts receivable, net |
|
|
5,081 |
|
|
|
5,798 |
|
|
Inventory |
|
|
11,074 |
|
|
|
15,462 |
|
|
Prepaid expenses and other current assets |
|
|
2,334 |
|
|
|
8,397 |
|
|
Total current assets |
|
|
65,271 |
|
|
|
121,106 |
|
|
Property and equipment, net |
|
|
664 |
|
|
|
2,860 |
|
|
Operating lease right-of-use assets |
|
|
2,974 |
|
|
|
2,455 |
|
|
Intangible assets, net |
|
|
661 |
|
|
|
2,292 |
|
|
Goodwill |
|
|
8,454 |
|
|
|
8,454 |
|
|
Other assets |
|
|
136 |
|
|
|
118 |
|
|
Total assets |
|
$ |
78,160 |
|
|
$ |
137,285 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
||||
|
Current liabilities: |
|
|
|
|
||||
|
Accounts payable |
|
$ |
1,176 |
|
|
$ |
4,438 |
|
|
Accrued expenses |
|
|
3,266 |
|
|
|
5,357 |
|
|
Accrued compensation |
|
|
2,758 |
|
|
|
3,616 |
|
|
Operating lease liabilities |
|
|
1,377 |
|
|
|
1,114 |
|
|
Current portion of term loan |
|
|
24,900 |
|
|
|
— |
|
|
Other current liabilities |
|
|
1,844 |
|
|
|
2,191 |
|
|
Total current liabilities |
|
|
35,321 |
|
|
|
16,716 |
|
|
Operating lease liabilities, net of current |
|
|
1,423 |
|
|
|
1,095 |
|
|
Term loan, net of current |
|
|
12,467 |
|
|
|
36,746 |
|
|
Other liabilities |
|
|
530 |
|
|
|
773 |
|
|
Total liabilities |
|
|
49,741 |
|
|
|
55,330 |
|
|
Commitments and contingencies |
|
|
|
|
||||
|
Stockholders’ equity: |
|
|
|
|
||||
|
Preferred stock, $0.001 par value; authorized —10,000,000 shares; issued and outstanding – none |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value; authorized — 500,000,000 shares as of December 31, 2023 and 2022; issued — 63,547,467 shares as of December 31, 2023 and 49,974,281 shares as of December 31, 2022; outstanding — 63,547,467 shares as of December 31, 2023 and 49,974,281 shares as of December 31, 2022 |
|
|
64 |
|
|
|
50 |
|
|
Additional paid-in-capital |
|
|
458,357 |
|
|
|
451,060 |
|
|
Accumulated other comprehensive gain (loss) |
|
|
11 |
|
|
|
(61 |
) |
|
Accumulated deficit |
|
|
(430,013 |
) |
|
|
(369,094 |
) |
|
Total stockholders’ equity |
|
|
28,419 |
|
|
|
81,955 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
78,160 |
|
|
$ |
137,285 |
|
|
SONENDO, INC. |
||||||||||||||||
|
CONSOLIDATED STATEMENTS OF |
||||||||||||||||
|
OPERATIONS AND COMPREHENSIVE LOSS |
||||||||||||||||
|
(In thousands, except share and per share data) |
||||||||||||||||
|
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
|
|
|
(Unaudited) |
|
|
|
|
||||||||||
|
Product revenue |
|
$ |
9,024 |
|
|
$ |
9,840 |
|
|
$ |
34,628 |
|
|
$ |
33,280 |
|
|
Software revenue |
|
|
2,668 |
|
|
|
2,390 |
|
|
|
9,237 |
|
|
|
8,376 |
|
|
Total revenue |
|
|
11,692 |
|
|
|
12,230 |
|
|
|
43,865 |
|
|
|
41,656 |
|
|
Cost of sales: |
|
|
|
|
|
|
|
|
||||||||
|
Product and software |
|
|
7,617 |
|
|
|
8,900 |
|
|
|
31,559 |
|
|
|
31,176 |
|
|
Impairment of long-lived assets |
|
|
243 |
|
|
|
— |
|
|
|
1,584 |
|
|
|
— |
|
|
Total cost of sales |
|
|
7,860 |
|
|
|
8,900 |
|
|
|
33,143 |
|
|
|
31,176 |
|
|
Gross profit |
|
|
3,832 |
|
|
|
3,330 |
|
|
|
10,722 |
|
|
|
10,480 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
|
Selling, general and administrative |
|
|
11,163 |
|
|
|
14,513 |
|
|
|
54,022 |
|
|
|
51,906 |
|
|
Research and development |
|
|
2,514 |
|
|
|
3,580 |
|
|
|
12,355 |
|
|
|
16,776 |
|
|
Impairment of long-lived assets |
|
|
37 |
|
|
|
— |
|
|
|
2,088 |
|
|
|
— |
|
|
Total operating expenses |
|
|
13,714 |
|
|
|
18,093 |
|
|
|
68,465 |
|
|
|
68,682 |
|
|
Loss from operations |
|
|
(9,882 |
) |
|
|
(14,763 |
) |
|
|
(57,743 |
) |
|
|
(58,202 |
) |
|
Other income (expense), net: |
|
|
|
|
|
|
|
|
||||||||
|
Interest and financing cost, net |
|
|
(994 |
) |
|
|
(469 |
) |
|
|
(3,174 |
) |
|
|
(3,228 |
) |
|
Employee retention credit |
|
|
— |
|
|
|
4,382 |
|
|
|
— |
|
|
|
4,382 |
|
|
Loss before income tax expense |
|
|
(10,876 |
) |
|
|
(10,850 |
) |
|
|
(60,917 |
) |
|
|
(57,048 |
) |
|
Income tax expense |
|
|
(2 |
) |
|
|
(2 |
) |
|
|
(2 |
) |
|
|
(2 |
) |
|
Net loss |
|
$ |
(10,878 |
) |
|
$ |
(10,852 |
) |
|
$ |
(60,919 |
) |
|
$ |
(57,050 |
) |
|
Other comprehensive income (loss) (net of tax): |
|
|
|
|
|
|
|
|
||||||||
|
Unrealized gain (loss) on marketable securities |
|
|
17 |
|
|
|
(12 |
) |
|
|
72 |
|
|
|
(61 |
) |
|
Net comprehensive loss |
|
$ |
(10,861 |
) |
|
$ |
(10,864 |
) |
|
$ |
(60,847 |
) |
|
$ |
(57,111 |
) |
|
Net loss per share attributable to common stock – basic and diluted |
|
$ |
(0.12 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.65 |
) |
|
$ |
(1.27 |
) |
|
Weighted-average shares outstanding – basic and diluted |
|
|
94,536,827 |
|
|
|
93,138,031 |
|
|
|
93,988,749 |
|
|
|
44,932,952 |
|
|
SONENDO, INC. |
||||||||||||||||
|
RECONCILIATION OF GAAP TO NON-GAAP |
||||||||||||||||
|
GROSS PROFIT AND GROSS MARGIN |
||||||||||||||||
|
(in thousands) |
||||||||||||||||
|
|
|
Three Months Ended December 31, |
|
|
Year Ended December 31, |
|
||||||||||
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
|
Gross profit |
|
$ |
3,832 |
|
|
$ |
3,330 |
|
|
$ |
10,722 |
|
|
$ |
10,480 |
|
|
Gross margin |
|
|
33 |
% |
|
|
27 |
% |
|
|
24 |
% |
|
|
25 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Impairment of long-lived assets |
|
|
243 |
|
|
|
— |
|
|
|
1,584 |
|
|
|
— |
|
|
Non-GAAP gross profit |
|
$ |
4,075 |
|
|
$ |
3,330 |
|
|
$ |
12,306 |
|
|
$ |
10,480 |
|
|
Non-GAAP gross margin |
|
|
35 |
% |
|
|
27 |
% |
|
|
28 |
% |
|
|
25 |
% |
|
SONENDO, INC. |
||||||||||||||||
|
RECONCILIATION OF GAAP TO NON-GAAP |
||||||||||||||||
|
LOSS FROM OPERATIONS |
||||||||||||||||
|
(In thousands) |
||||||||||||||||
|
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
|
GAAP loss from operations |
|
$ |
9,882 |
|
|
$ |
14,763 |
|
|
$ |
57,743 |
|
|
$ |
58,202 |
|
|
Adjustments: |
|
|
|
|
|
|
|
|
||||||||
|
Stock based compensation: |
|
|
|
|
|
|
|
|
||||||||
|
Included in cost of sales |
|
|
(65 |
) |
|
|
(198 |
) |
|
|
(359 |
) |
|
|
(562 |
) |
|
Included in selling, general and administrative |
|
|
(1,301 |
) |
|
|
(1,909 |
) |
|
|
(6,228 |
) |
|
|
(5,729 |
) |
|
Included in research and development |
|
|
(125 |
) |
|
|
(304 |
) |
|
|
(689 |
) |
|
|
(1,191 |
) |
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
||||||||
|
Included in cost of sales |
|
|
(67 |
) |
|
|
(202 |
) |
|
|
(807 |
) |
|
|
(709 |
) |
|
Included in selling, general and administrative |
|
|
(22 |
) |
|
|
(242 |
) |
|
|
(780 |
) |
|
|
(855 |
) |
|
Included in research and development |
|
|
(22 |
) |
|
|
(30 |
) |
|
|
(116 |
) |
|
|
(152 |
) |
|
Impairment of long-lived assets |
|
|
|
|
|
|
|
|
||||||||
|
Included in cost of sales |
|
|
(243 |
) |
|
|
— |
|
|
|
(1,584 |
) |
|
|
— |
|
|
Included in operating expenses |
|
|
(37 |
) |
|
|
— |
|
|
|
(2,088 |
) |
|
|
— |
|
|
Non-GAAP loss from operations |
|
$ |
8,000 |
|
|
$ |
11,878 |
|
|
$ |
45,092 |
|
|
$ |
49,004 |
|
Contacts
Investor Contact:
Gilmartin Group
Greg Chodaczek
IR@Sonendo.com
SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO),…
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology…
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX,…
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX:…
WESTBROOK, ME / ACCESSWIRE / June 7, 2024 / What Happened?We discovered unauthorized access on…
Charlotte, North Carolina--(Newsfile Corp. - June 7, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…